Yes, continue both medications - this combination is strongly recommended and evidence-based
You should continue empagliflozin (Jardiance) 10 mg once daily and metformin 1000 mg twice daily. This combination represents guideline-concordant therapy for type 2 diabetes and is specifically recommended by the highest-quality evidence available 1, 2.
Why This Combination is Recommended
The 2020 KDIGO guidelines and 2022 ADA/KDIGO consensus explicitly recommend treating patients with type 2 diabetes using both metformin AND an SGLT2 inhibitor (like empagliflozin) together 1, 2. This is not just acceptable - it's the preferred approach for most patients.
Metformin Component (1000 mg twice daily)
Your current metformin dose is appropriate as long as your eGFR is ≥30 mL/min/1.73 m² 1, 2. The guidelines specify:
- Continue full dose if eGFR ≥60: No adjustment needed
- Consider dose reduction if eGFR 45-59: May reduce to 1000 mg total daily in certain high-risk situations
- Reduce to 1000 mg total daily if eGFR 30-44: Your current 2000 mg daily would need reduction
- Stop if eGFR <30: Contraindicated 2
Critical monitoring: Check your eGFR at least annually if ≥60, or every 3-6 months if 45-59 1.
Empagliflozin Component (10 mg once daily)
Your empagliflozin dose is appropriate and should be continued for multiple reasons beyond glucose control 2:
- Cardiovascular protection: Reduces cardiovascular death and heart failure hospitalization 3
- Kidney protection: Slows CKD progression and reduces albuminuria 2
- Can be initiated down to eGFR ≥20 mL/min/1.73 m² and continued even if eGFR falls below this threshold 1, 2
The FDA label confirms empagliflozin 10 mg is the recommended starting dose for cardiovascular and kidney benefits 3.
Evidence Supporting This Combination
Multiple high-quality studies demonstrate empagliflozin added to metformin produces:
- Superior HbA1c reduction: -0.7% to -0.8% greater reduction versus placebo when added to metformin 4, 5
- Weight loss: Additional 2-3 kg reduction beyond metformin alone 4, 6
- Blood pressure reduction: Sustained decreases in systolic BP 6
- Maintained efficacy long-term: Benefits sustained through 76 weeks 6
A 2025 meta-analysis confirmed empagliflozin provides superior glycemic and cardiometabolic benefits compared to alternative add-on agents like sitagliptin 7.
Important Safety Considerations
Monitor for These Specific Issues:
Genital mycotic infections (3.7-4.7% incidence with empagliflozin):
- Practice daily genital hygiene
- Most infections are easily treated
- Seek care if severe symptoms develop 2
Volume depletion (especially if on diuretics):
Diabetic ketoacidosis (rare but serious):
- Stop empagliflozin 3-4 days before any surgery 3
- Hold during acute illness, prolonged fasting, or critical medical conditions
- Monitor for nausea, vomiting, abdominal pain, shortness of breath
- Can occur even with normal blood glucose 2, 3
Vitamin B12 deficiency (from metformin):
- Monitor B12 levels, especially after 4+ years of metformin use 2
When to Temporarily Stop Empagliflozin:
- Before scheduled surgery (3-4 days prior)
- During acute illness or critical medical conditions
- During prolonged fasting periods
- If signs of ketoacidosis develop 1, 3
Common Pitfall to Avoid
Do not stop empagliflozin if you see a small, reversible eGFR decrease after starting it - this is expected and generally not a reason to discontinue 1. The kidney and cardiovascular benefits persist even as glucose-lowering effects diminish at lower eGFR levels 2.
Dosing Adjustments Based on Kidney Function
Your medications should be adjusted as follows based on eGFR:
If eGFR 30-44 mL/min/1.73 m²:
If eGFR <30 mL/min/1.73 m²:
- Metformin: Stop (contraindicated) 2
- Empagliflozin: Continue for cardiovascular/kidney benefits (though glucose-lowering effect minimal) 1, 2
If on dialysis:
- Metformin: Contraindicated
- Empagliflozin: Contraindicated 3